Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-09-03

Clinical Trial Update: A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating milnacipran's effects on 24-hour ambulatory blood pressure in fibromyalgia patients, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAVELLA (milnacipran hydrochloride)

Snippet

Sponsor: Forest Laboratories | Conditions: Fibromyalgia | Phase 3 | Status: COMPLETED | Results posted: 2009-09-03